Navigation Links
Actuate Therapeutics Announces Initiation Of Phase 2 Clinical Study In Pancreatic Cancer

Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as a new arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3ß) inhibitor which is being developed for adults and children with advanced refractory cancers.

The pancreatic phase 2 1801 study arm is open-label and designed to evaluate the efficacy of 9-ING-41 in combination with gemcitabine/nab-paclitaxel as treatment of patients with advanced pancreatic cancer in the first-line setting. The study will enroll up to 60 evaluable US and EU patients in a Simon two-stage design, with the primary objective of assessing the disease control rate of the 9-ING-41-based combination regimen.
Actuate is also recruiting patients for their 1901 international phase 2 study of 9-ING-41 as a single agent and in combination with Ruxolitinib in patients with advanced refractory myelofibrosis, (NCT04218071), already open in the U.S. and opening in the U.K.
“The data we presented on the 1801 study at this year’s ASCO annual meeting, showing prolonged disease stability in patients with metastatic pancreatic cancer who were refractory to several prior lines of chemotherapy, continue to impress” said Dr. Benedito Carneiro, MD, Principle Investigator on the 1801 study at Brown University, Lifespan Cancer Institute, and presenter of the ASCO 1801 oral abstract ( “We have very positive safety data on 9-ING-41 in a cohort of over 200 heavily pre-treated patients on the 1801 study with objective responses being observed with both single agent 9-ING-41 and when it is combined with standard cytotoxic regimens including with gemcitabine/nab-paclitaxel. We are thus particularly excited to have this study open for our patients as we are to have both the myelofibrosis and pediatric studies of 9-ING-41.”

“Pancreatic cancer continues to be one of the deadliest cancers, with less than 10% survival in the US at 5 years. New therapies are desperately needed for this patient population” said Dr. Anwaar Saeed, MD, Principle Investigator on the 1801 study at the University of Kansas, Kansas City. “The pre-clinical data on 9-ING-41 in pancreatic cancer is compelling with evidence of multiple modes of action. The pre-clinical evidence of 9-ING-41’s potent anti-fibrotic activity is also intriguing not alone in the context of pancreatic cancer but also in the sarcomas, where 9-ING-41 has significant pre-clinical activity in a broad spectrum of models of both adult and pediatric disease. We are looking forward to evaluating the combination of this novel safe targeted agent with standard regimens in patients with advanced pancreatic cancer setting on both the 1801 phase 2 study and potentially with other cytotoxic regimens, including FOLFIRINOX as frontline therapy.”

“We are delighted to move the first clinically relevant GSK-3B inhibitor into phase 2 studies in both myelofibrosis and pancreatic cancer” said Ludimila Cavalcante, MD, Medical Director at Actuate Therapeutics. “In parallel with our clinical program, our collaborations focused on pre-clinical work in pancreatic cancer models with colleagues including Dr. Daniel Billadeau at the Mayo Clinic and Dr. Holly Brunton at the University of Glasgow are also expanding. In addition to 9-ING-41’s direct anti-neoplastic and anti-fibrotic activities, we are examining its potential to synergize with immune-modulatory approaches, with an initial focus on melanoma and neuroblastoma. I am particularly excited about the caliber and range of investigator-initiated studies being developed by our clinical colleagues with whom we are indeed fortunate to collaborate.”

“The opening of this phase 2 study evaluating 9-ING-41 as a potential key component of first line therapy in advanced pancreatic cancer represents another major milestone for Actuate.” said Daniel Schmitt, President & CEO. “Based on the compelling preclinical data developed by leading researchers on the effect of GSK-3ß inhibition in cancer and fibrotic diseases, and the clinical profile demonstrated by 9-ING-41 to date, we are hopeful that employing 9-ING-41 in first line treatment of pancreatic cancer will bring additional clinical benefit to patients and offer a new therapeutic option in treating this challenging and devastating disease.”

About Actuate Therapeutics, Inc.
Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases. For additional information, please visit the Company’s website at

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related medicine news :

1. Actuate Therapeutics Announces Initiation of Additional Clinical Studies for 9-ING-41
2. Temprian Therapeutics Finalist in Nature Merck Spinoff 2020 Competition
3. Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation
4. EMulate® Therapeutics Announces Multiple Presentations on the Voyager and Hælo® systems
5. Better Therapeutics Demonstrates Proof of Concept in the Use of Digital Biomarkers to Improve Treatment Outcomes
6. FDA Accepts for Filing the Humanitarian Device Exemption Application For EMulate Therapeutics™ Hælo™ Pediatric System
7. Neutron Therapeutics Installs Europe’s First Accelerator-Based Boron Neutron Capture Therapy (BNCT) Platform – On Track for First Cancer Patient Treatment in 2019
8. Saol Therapeutics Announces CDC has Updated Information Related to Use and Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
9. uBiome Receives Patent for Diagnostics and Therapeutics for Endocrine System Conditions
10. uBiome Receives Patent for Diagnostics and Therapeutics for Microbiome Functional Features
11. Madam Therapeutics Closes €1.1 Million Financing Round to Develop Novel Antibiotics Against Drug Resistant Bacteria
Post Your Comments:
(Date:9/3/2020)... ... September 03, 2020 , ... ... American Foundation for Suicide Prevention’s (AFSP) annual signature event, Out of the Darkness ... of U.S. cities to raise awareness of suicide prevention. To ensure Associate safety, ...
(Date:9/3/2020)... ... 2020 , ..., a comprehensive resource for caregivers and ... in Louisville, KY. The guide identifies 17 memory care communities based on location, ... Alzheimer’s Association , 5.6 million people age 65 and older are living with ...
(Date:9/1/2020)... , ... September 01, 2020 , ... ... new practice in Glendale. While the office will be the first to ... augmentation, tummy tucks, buttock augmentation (Brazilian butt lift), as well as rhinoplasty, facial ...
(Date:9/1/2020)... , ... September 01, 2020 , ... As fall and ... the Cohn Health Institute has taken this time to expand and grow ... its 30th Anniversary, the Cohn Health Institute will be relaunching its brand new website, ...
(Date:8/31/2020)... ... August 31, 2020 , ... The Lymphoma ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... Anniversary of Blood Cancer Awareness Month (BCAM) and its international Light it ...
Breaking Medicine News(10 mins):
(Date:9/2/2020)... ... September 02, 2020 , ... ... will moderate a roundtable discussion among industry professionals about successes and challenges of ... by American Pharmaceutical Review and will take place on October 15, ...
(Date:9/1/2020)... ... September 01, 2020 , ... ... appointed to serve as Secretary to the Board of Trustees and committee chair ... High United Way is a Denver-based nonprofit organization that fights for the education, ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... If you live in New York City ... real estate part makes sense, it’s the law of supply and demand, but are plastic ... has a significant percentage of their patients that make the four-hour trip to have ...
Breaking Medicine Technology: